Halcion Shortage: What Providers and Prescribers Need to Know in 2026

Patients presenting for triazolam (Halcion) refills are increasingly reporting difficulty filling their prescriptions — and this is generating additional administrative burden for practices. This clinical briefing summarizes the current supply situation for triazolam, offers evidence-based alternatives for patients who cannot access it, and identifies tools to streamline the process of helping patients find their medication.

Current Supply Status: Official vs. Functional Availability

As of 2026, triazolam is not listed on the FDA Drug Shortages database or the ASHP shortage list. The drug continues to be manufactured by multiple generic producers including Teva Pharmaceuticals, Perrigo, Apotex, and Zydus Pharmaceuticals.

However, the drug's declining prescription volume — down more than 50% since 2010 — has resulted in a functional undersupply at the point of dispensing. Many retail pharmacies, particularly chain locations, carry minimal triazolam inventory or none at all. This is particularly true for the 0.125 mg dose, which is less commonly prescribed and therefore even less reliably stocked.

Drug Profile: Clinical Considerations for Prescribers

Triazolam is a triazolobenzodiazepine with a mean plasma elimination half-life of 1.5 to 5.5 hours — among the shortest of all benzodiazepine hypnotics. It is FDA-approved for the short-term treatment of insomnia in adults, with recommended use limited to 7 to 10 days. Key pharmacological features include:

• Mechanism: GABA-A receptor positive allosteric modulator at the benzodiazepine binding site
• Metabolism: Primarily CYP3A4; significant interactions with strong inhibitors (ketoconazole, itraconazole, nefazodone, most HIV protease inhibitors — all contraindicated)
• Dosing: 0.25 mg at bedtime (standard); 0.125 mg for elderly and low body weight patients; maximum 0.5 mg
• DEA Schedule: Schedule IV (C-IV)
• Black box warnings: Concomitant use with opioids (profound sedation/respiratory depression/death); abuse, misuse, addiction, physical dependence, and withdrawal (updated September 2020)

Why Triazolam Availability Has Declined

The clinical landscape shifted dramatically against triazolam in the 1990s following reports of anterograde amnesia, paradoxical behavioral reactions, and regulatory action in the UK. These safety concerns — combined with the arrival of zolpidem and other Z-drugs — drove a sustained decline in prescribing. In 2017, triazolam was the 289th most commonly prescribed drug in the US, with just over 1 million prescriptions annually. That number has continued to fall.

From a pharmacoeconomic perspective, generic manufacturers have little incentive to maintain high production volumes for a low-demand, low-margin drug. DEA manufacturing quotas for Schedule IV substances further constrain supply. The result is a drug that remains FDA-approved but is structurally undersupplied at the pharmacy level.

When to Consider Maintaining Triazolam vs. Switching

Triazolam's ultra-short half-life provides a genuine clinical advantage in some specific situations:

• Sleep-onset insomnia where next-morning sedation is a high-priority concern
• Jet lag management or circadian rhythm disruption (rapid onset, rapid clearance)
• Patients who have failed other sleep medications and tolerate triazolam well
• Procedural sedation — some providers use triazolam as pre-procedural anxiolytic for dental or minor procedures

For most other clinical presentations of insomnia, alternatives are clinically equivalent and more reliably available. The trend in evidence-based insomnia treatment is toward CBT-I as first-line and DORAs (suvorexant, lemborexant) as pharmacological second-line, with benzodiazepines reserved for specific situations.

Therapeutic Alternatives: Equivalence and Substitution Guide

When transitioning patients off triazolam, note that abrupt discontinuation should be avoided — particularly in patients using for more than 2 weeks. A graduated taper is recommended. Approximate benzodiazepine equivalences:

• Triazolam 0.25 mg ≈ Temazepam 15 mg ≈ Diazepam 10 mg (for cross-taper reference only; individual response varies)

Preferred alternatives by clinical profile:

• Temazepam (Restoril) 15–30 mg: Most pharmacologically similar; intermediate half-life (8–15 hr); widely available; Schedule IV
• Zolpidem IR (Ambien) 5–10 mg: Widely available; similar onset; Z-drug mechanism; Schedule IV; lower amnestic risk than triazolam
• Eszopiclone (Lunesta) 1–3 mg: FDA-approved for chronic insomnia; both sleep-onset and maintenance; Schedule IV
• Suvorexant (Belsomra) 10–20 mg or Lemborexant (Dayvigo) 5–10 mg: DORAs; lower dependence risk; no anterograde amnesia; Schedule IV; cost may be limiting without insurance
• Doxepin low-dose (Silenor) 3–6 mg: Non-scheduled; sleep maintenance only; antihistaminergic mechanism; prescribable at telehealth encounters

Insurance and Coverage Notes for Prescribers

Prescribers should be aware of the Medicare Part D coverage situation for benzodiazepines: most Medicare Part D plans do not cover benzodiazepines prescribed for insomnia. This is a critical issue for elderly patients who may face the full cash price — approximately $15–$50 for 30 tablets of generic triazolam at retail, or as low as $3.99–$18.80 with GoodRx or similar discount coupons.

There is no manufacturer patient assistance program for generic triazolam. Patients can be directed to NeedyMeds.org or RxAssist.org for general assistance resources. GoodRx, SingleCare, and RxSaver coupons are available and may reduce cost significantly at participating pharmacies.

How to Help Your Patients Find Triazolam

When patients report difficulty filling their triazolam prescription, recommend they use medfinder for Providers. This service calls pharmacies in the patient's area to identify which ones have the medication in stock, eliminating the need for patients to make dozens of calls. For practices managing multiple patients with this issue, medfinder's provider portal offers a streamlined solution.

Independent pharmacies remain the most reliable option for triazolam, as they stock based on their patient population's specific needs and have more flexible ordering practices than chains. Hospital outpatient pharmacies are another reliable source.

Clinical Takeaways for Prescribers

• Triazolam is not in an official FDA shortage, but functional undersupply is real and affects many patients
• Proactively counsel patients on refill timing — recommend filling 3–5 days before running out
• For new insomnia patients, consider whether triazolam is the best first-line choice given availability and the availability of equally effective, more easily accessible alternatives
• Patients on chronic triazolam should be counseled about tapering and not to abruptly discontinue if their pharmacy is out
• Direct patients to medfinder or independent pharmacies to minimize prescription fill delays

See also our companion guide: How to Help Your Patients Find Halcion in Stock: A Provider's Guide.